Clinical Trials

Currently, SOTIO Biotech is conducting a Phase 1 & 2 clinical trials to evaluate the efficacy and safety of nanrilkefusp alfa (formerly SOT101) as monotherapy and in combination with other treatments. The company is also running a Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of SOT102 in monotherapy and in combination with established standard of care therapies. In coming months, SOTIO plans to initiate the first-in-human clinical trial for its CAR T cell therapy candidate, BOXR1030 as well as a Phase 2 study of nanrilkefusp alfa in combination with cetuximab.